Hospital use systemic antifungal drugs

BMC Clinical Pharmacology

Volumn 5, Issue , 2005, Pages

  de With, Katja ^a   Steib Bauert, Michaela ^a   Knoth, Holger ^b   Dörje, Frank ^c   Strehl, Egid ^a   Rothe, Ulrich ^d   Maier, Ludwig ^e   Kern, Winfried V ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG RESISTANCE; DRUG USE; HOSPITAL CARE; HOSPITAL DEPARTMENT; HOSPITAL SERVICE; HUMAN; INTENSIVE CARE UNIT; MEDICAL RECORD; PRESCRIPTION; SYSTEMIC THERAPY; UNIVERSITY HOSPITAL; COMPARATIVE STUDY; GERMANY; HOSPITAL PHARMACY;

ANTIFUNGAL AGENTS; FLUCONAZOLE; GERMANY; HOSPITALS, UNIVERSITY; HUMANS; PHARMACY SERVICE, HOSPITAL; SURGERY DEPARTMENT, HOSPITAL;

EID: 27544504784     PISSN: 14726904     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-5-1     Document Type: Article

References (21)

1. Carton JA, Maradona JA, Perez del Molino G, Asensi V: Trends observed in the use of antimicrobial agents at a Spanish hospital from 1986 and 1991. Med Clin (Barc) 1993, 100:761-765.
2. Grasela TH, Goodwin SD, Pasko MT, Walawander CA, Raebel MA: Use of antifungal therapy in hospitalized patients. I. Results prior to the marketing of fluconazole. Ann Pharmacother 1994, 28:252-260.
3. Grasela TH, Pasko MT, Goodwin SD, Walawander CA, Backwelder N, Bruder-Holt RJ: Use of antifungal therapy in hospitalized patients. II. Results after the marketing of fluconazole. Ann Pharmacother 1994, 28:261-270.
4. Gutierrez F, Wall P, Cohen J: An analysis of the trends in the use of antifungal drugs and fungal isolates in a UK University Hospital. J Hosp Infect 1995, 31:149-152.
5. Cars O, Ekdahl K: A Report on Swedish Antibiotic Utilisation and Resistance in Human Medicine Stockholm, The Swedish Strategic Programme for the Rational Use of Antimicrobial Agents (STRAMA) and the Swedish Institute for Infectious Disease Control; 2002:1-36.
6. Chen YC, Chang SC, Luh KT, Hsieh WC: Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003, 52:71-77.
7. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Tauber MG, Pittet D, Fungal Infection Network of Switzerland: Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004, 38:311-320.
8. Denning D: Antifungals. Where are we headed? DrugPlus international (21 September 2004) http://pharmalicensing.com/articles/disp/1095693369_414ef439d6909. accessed 15.10.2004
9. Alvarez-Lerma F, Nolla J, Palomar M, Leon MA: Treatment approach for fungal infections in critically ill patients admitted to intensive care units: results of a multicenter survey. Enferm Infecc Microbiol Clin 2003, 21:83-88.
10. Trifilio S, Verma A, Mehta J: Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004, 33:735-739.
11. Gutierrez F, Wall PG, Cohen J: An audit of the use of antifungal agents. J Antimicrob Chemother 1996, 37:175-185.
12. Gallagher JC, Macdougall C, Dodds Ashley ES, Perfect JR: Recent advances in antifungal pharmacotherapy for invasive fungal infections. ExpertRev Anti Infect Ther 2004, 2:253-268.
13. Nucci M: Emerging moulds: Fusarium, Scedosporium and zygomycetes in transplant recipients. Curr Opin Infect Dis 2003, 16:607-612.
14. Mathema B, Cross E, Dun E, Park S, Bedell J, Slade B, Williams M, Riley L, Chaturvedi V, Perlin DS: Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 2001, 33:E23-E27.
15. McCaig LF, McNeil MM: Trends in prescribing for vulvovaginal candidiasis in the United States. Pharmacoepidemiol Drug Saf. published online 19 Mar 2004
16. Hudson MM: Antifungal resistance and over-the-counter availability in the UK: a current perspective. J Antimicrob Chemother 2001, 48:345-350.
17. Kern WV, Rose AD, Hay B, Muche R, Frank U, Baden-Württemberg Interuniversity Study Group: Antimicrobial expenditures and usage at four university hospitals. Infection 2001, 29:127-137.
18. Kern WV, De With K, Gonnermann C, Strehl E, the MABUSE-INTERUNI-II Project Group: Update on glycopeptide use in German university hospitals. Infection 2004, 32:157-162.
19. De With K, Bergner J, Bühner R, Dörje F, Gonnermann C, Haber M, Hartmann M, Rothe U, Strehl E, Steib-Bauert M, Kern WV: Antibiotic use at German university hospitals (Project INTERUNI-II). Results for medical intensive care, hematology-oncology, and other medical service areas. Med Klin (Munich) 2004, 99:347-354.
20. Natsch S, Steeghs MH, Hekster YA, Meis JF, van der Meer JW, Kullberg BJ: Use of fluconazole in daily practice: still room for Improvement. J Antimicrob Chemother 2001, 48:303-310.
21. Moody SB, Sveska KJ: Fluconazole dosing in renal impairment: a drug usage evaluation. Hosp Formul 1993, 28:499-502.